×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Mankind Pharma Limited | 26055.8 | 4127.6 | 25413.6 | 9.99 | 1,06,467 | 56.3 |
| DR.REDDYS LABORATORIES LTD. | 88624.0 | 14099.0 | 85721.0 | 17.02 | 106162 | 18.7 |
| Zydus Lifesciences Limited | 27454.0 | 3847.0 | 25883.0 | 3.82 | 103582 | 22.2 |
Mankind Pharma Limited, with Security Code 543904, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,872.1 | 2,300.2 | 2,453.3 | 2,358.6 | 2,152.7 | 2,403.3 | 2,529.7 | 2,396.6 | 2,126.6 | 2,541.4 |
| Expenses | 1,491.0 | 1,760.7 | 1,818.2 | 1,755.5 | 1,605.4 | 1,831.1 | 1,777.7 | 1,655.6 | 1,649.7 | 1,868.3 |
| Operating Profit | 381.2 | 539.5 | 635.2 | 603.1 | 547.3 | 572.2 | 752.0 | 740.9 | 476.9 | 673.1 |
| OPM % | 20.36% | 23.45% | 25.89% | 25.57% | 25.43% | 23.81% | 29.73% | 30.92% | 22.43% | 26.48% |
| Other Income | 42.5 | 57.4 | 58.1 | 67.2 | 83.9 | 94.8 | 105.8 | 69.8 | 219.3 | 64.2 |
| Interest | 0.9 | 2.0 | 4.3 | 4.3 | 4.0 | 6.3 | 1.9 | 199.5 | 162.3 | 146.7 |
| Depreciation | 67.3 | 68.5 | 77.0 | 89.7 | 82.3 | 83.4 | 85.4 | 87.0 | 105.2 | 96.9 |
| Profit before tax | 355.4 | 526.4 | 612.0 | 576.4 | 544.9 | 577.4 | 770.5 | 524.3 | 428.8 | 493.7 |
| Tax % | -20.9% | -22.2% | -22.7% | -15.5% | -16.6% | -16.1% | -21.8% | 20.6% | 10.8% | 16.4% |
| Net Profit | 281.0 | 409.3 | 472.9 | 487.1 | 454.2 | 513.5 | 634.4 | 416.4 | 382.5 | 412.8 |
| EPS in Rs | 7.01 | 10.21 | 11.79 | 12.14 | 11.32 | 12.8 | 15.81 | 10.33 | 18.5 | 9.99 |
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,052.7 | 2,578.6 | 2,708.1 | 2,607.0 | 2,441.1 | 2,893.4 | 3,076.5 | 3,230.0 |
| Expenses | 1,636.0 | 1,923.8 | 2,025.5 | 2,000.5 | 1,850.0 | 2,211.7 | 2,226.5 | 2,400.2 |
| Operating Profit | 416.7 | 654.8 | 682.6 | 606.5 | 591.1 | 681.8 | 850.0 | 829.8 |
| OPM % | 20.3% | 25.39% | 25.21% | 23.26% | 24.21% | 23.56% | 27.63% | 25.69% |
| Other Income | 47.5 | 58.6 | 60.0 | 70.1 | 92.1 | 100.6 | 109.4 | 77.3 |
| Interest | 5.2 | 6.3 | 8.6 | 9.2 | 9.4 | 10.9 | 7.1 | 220.9 |
| Depreciation | 84.5 | 87.4 | 96.5 | 109.7 | 104.7 | 107.7 | 105.6 | 192.3 |
| Profit before tax | 374.5 | 619.7 | 637.5 | 557.7 | 569.2 | 663.7 | 846.8 | 493.9 |
| Tax % | -22.3% | -21% | -20.4% | -18.4% | -16.7% | 18.8% | 22.5% | -22.8% |
| Net Profit | 293.7 | 494.2 | 511.2 | 459.8 | 476.6 | 543.1 | 658.9 | 384.5 |
| EPS in Rs | 7.13 | 12.14 | 12.49 | 11.31 | 11.74 | 13.37 | 16.28 | 9.44 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 15% |
| 3 Years: | 8% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 15% |
| 3 Years: | 12% |
| TTM: | 10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| 1 Year: | 16% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 16% |
| 3 Years: | 16% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 15% |
| 3 Years: | 13% |
| TTM: | 10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| 1 Year: | 16% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|